Over the past few years, Abbott Laboratories' (NYSE: ABT) business has been a bit of a roller coaster. The pandemic disrupted its medical device business, but it was later able to smooth out those ...

Abbott Laboratories' diabetes care segment recently added new products to its lineup. It should remain one of the company's key growth drivers over the long run. There are other good reasons to ...

Abbott's medtech division has consistently contributed to overall growth, with expectations for double-digit expansion from 2024 to 2026. Abbott's stock is currently valued at 22.3 times the ...

On Thursday, Piper Sandler initiated coverage on Abbott Laboratories (NYSE:NYSE:ABT) stock, assigning an Overweight rating and setting a price target of $131. The firm highlighted the company's ...

In a report released yesterday, Larry Biegelsen from Wells Fargo maintained a Buy rating on Abbott Laboratories (ABT – Research Report), with a price target of $133.00. The company’s shares ...

In a report released today, Patrick Wood from Morgan Stanley maintained a Hold rating on Abbott Laboratories (ABT – Research Report), with a price target of $107.00. Patrick Wood has given his ...

The projected fair value for Abbott Laboratories is US$132 based on 2 Stage Free Cash Flow to Equity With US$116 share price, Abbott Laboratories appears to be trading close to its estimated fair ...

Fintel reports that on September 19, 2024, Piper Sandler initiated coverage of Abbott Laboratories (NYSE:ABT) with a Overweight recommendation. As of August 26, 2024, the average one-year price ...

On Thursday, Piper Sandler initiated coverage on Abbott Laboratories (NYSE:NYSE:ABT) stock, assigning an Overweight rating and setting a price target of $131. The firm highlighted the company's strong ...

Shares of Abbott Laboratories ABT sank 0.37% to $116.40 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 0.54% to 5,626.02 ...